CTRI/2022/03/040718
Recruiting
未知
Efficacy And Safety of Injection Tenecteplase in 4.5 to 24 hours imaging Eligible Window patients with Acute Ischemic Stroke. - EAST-AIS
Department of Science and Technology Science and Engineering Research Board Government of India0 sites0 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Department of Science and Technology Science and Engineering Research Board Government of India
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Age \> 18 years
- •\-Acute Ischemic Stroke symptom onset within past 4\.5\-24 hours
- •\-Acute Ischemic Stroke consistent within ICA, MCA or ACA territory
- •\-Baseline mRS 0\-2
- •\-NIHSS score of \>5 at baseline and prior to randomization
- •\-Iimaging eligibility with perfusion lesion\-ischemic core mismatch greater than 1\.8 between the volume of hypoperfusion and volume of the ischemic core, an absolute difference in volume greater than 10 ml, and an ischemic\-core volume of less than 70 ml.
Exclusion Criteria
- •\-Imaging shows more than 1/3 of MCA territory infarct or more than one vascular territory
- •\-Acute or previous intracranial hemorrhage
- •\-Active internal organ bleeding
- •\- Known hypersensitivity to tenecteplase
- •\- Seizures at stroke onset
- •\-Severe, uncontrolled hypertension
- •\- Treatment with a thrombolytic within last 3 months
- •\-Prior ischemic stroke, severe head trauma, intracranial/intraspinal injury within 3 months
- •\-Gastrointestinal malignancy or GI bleed within 21 days
- •\-Occlusion in \> 1 vascular territory
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Safety and Efficacy of intra-arterial Tenecteplase for non-complete reperfusion of intracranial occlusioAcute ischemic strokes with incomplete reperfusionTherapeutic area: Not possible to specifyCTIS2022-502878-16-00Insel Gruppe AG10
Not yet recruiting
Phase 1
Tenecteplase (TNK) in the Treatment of Intracerebral Hemorrhage (ICH)Intracerebral HemorrhageIntracranial HemorrhagesHemorrhagic StrokesNCT06696131Gaurav Gupta, MD5
Terminated
Phase 2
To assess if the administration of a clot busting medication (Tenecteplase) administered at the site of the clot in the brain following intravenous administration of the clot busting medication is safe and feasible in patients with acute ischaemic stroke within 4.5 hours of symptom onset.Ischaemic strokeStroke - IschaemicACTRN12621000696897orthern Sydney Local Health District3
Completed
Phase 3
Safety and Efficacy of Intra-arterial Tenecteplase for Noncomplete Reperfusion of Intracranial OcclusionsIschemic StrokeNCT05499832Insel Gruppe AG, University Hospital Bern156
Recruiting
Phase 2
Efficacy of injectable transamine in patients with benign prostatic hyperplasiaBenign prostate enlargement.Benign neoplasm of prostateD29.1IRCT20211121053127N1Esfahan University of Medical Sciences70